Oculis Holding AG Share Price & Technical Analysis
OCS · $29.49 (-4.87%)
Healthcare / Biotechnology
$29.49
-4.87%
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidat…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
7% return in May, 2% avg return in past 3 year May month.
46% return in 2026, 32% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 41% | 3% | -8% | 2% | 7% | – | – | – | – | – | – | – | 46% |
| 25 | 36% | -14% | -3% | -9% | 13% | -2% | -9% | -9% | 8% | 10% | -2% | 5% | 24% |
| 24 | 15% | -11% | 0% | 8% | -9% | 2% | -3% | 3% | 3% | 42% | -8% | 8% | 51% |
| 23 | 0% | -8% | -25% | 48% | 4% | 10% | -1% | 7% | -16% | -13% | 5% | 10% | 20% |
| 22 | 1% | -1% | 0% | 1% | 0% | 0% | 1% | 1% | 0% | 1% | 0% | 1% | 5% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.76B
P/E ratio
—
52W high
$34.48
52W low
$16.00
Volume
4,87,736
Beta
0.20
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Oculis Holding AG share price today?
- Oculis Holding AG (OCS) last traded around $29.49 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OCS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OCS. Download the app for real-time alerts.
- How can I analyze Oculis Holding AG stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.